Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Annovis Bio Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York City. This presentation provides a significant opportunity for the company to showcase its progress and strategic direction to a global investment audience.
The conference appearance underscores Annovis Bio's ongoing commitment to addressing neurodegeneration in diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). The company's participation in high-profile investment conferences is crucial for maintaining visibility within the financial community and attracting potential investment to support its research and development efforts. For investors seeking additional information, the latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
Annovis Bio's focus on developing innovative therapies that improve patient outcomes and quality of life represents an important advancement in the treatment of neurodegenerative conditions. These diseases affect millions of patients worldwide and represent a significant unmet medical need. The company's research efforts contribute to the broader pharmaceutical industry's pursuit of effective treatments for these challenging conditions.
The H.C. Wainwright conference serves as a platform for emerging biotechnology companies to connect with investors and stakeholders. Annovis Bio's presentation at this event demonstrates the company's active engagement with the investment community and its commitment to transparent communication about its development programs. The conference timing in September 2025 allows the company to potentially share updates on clinical progress and future development plans.
InvestorWire, the communications platform that distributed this announcement, provides specialized wire-grade press release syndication services as part of the Dynamic Brand Portfolio. The platform offers enhanced press release distribution and social media dissemination through its network, helping companies like Annovis Bio reach target markets and diverse industries effectively. Additional information about these services is available at https://www.InvestorWire.com.